3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Multiple Myeloma
4
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Plasmacytoma
2
Paraproteinemias
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, Plasma Cell
2
Carcinoma, Non-Small-Cell Lung
2
Patient Preference
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Inflammatory Breast Neoplasms
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
CD20-positive Hematological Malignancies
1
Bile Duct Neoplasms
1
Advanced Solid Tumors
1
Advanced Cancers
1
Interventions
pertuzumab
1
pazopanib
1
decitabine and cedazuridine drug combination
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Radiotherapy
1
Opdualag
1
Nivolumab
1
Injections, Subcutaneous
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Patient Preference
×
Injections, Subcutaneous
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts